TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18473286
Drug: Benfotiamine 600
Normalized name: BENFOTIAMINE
DrugBank: Benfotiamine (DB11748)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine 600 mg per day
Study: 18473286
Drug: Benfotiamine 300
Normalized name: Benfotiamine 300mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine 300 mg per day
Study: 8519722
Drug: Fentanyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (10 micrograms/mL)
Study: 27128357
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment as Usual (TAU)
Study: 27128357
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) plus Treatment as Usual (TAU)
Study: 24785463
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of both techniques
Study: 15863798
Drug: Sibutramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (up to 15 mg/day)
Study: 12195728
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg orally for 3 months)
Study: 12195728
Drug: Metoclopramide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (5 mg intravenously)
Study: 7727324
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose 1 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.2 mg/mL morphine at an infusion rate of 0.8 mL/hr
Study: 7727324
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose 0.5 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.1 mg/mL morphine at an infusion rate of 0.8 mL/hr
Study: 2109522
Drug: Tenoretic (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoretic (100 mg atenolol + 25 mg chlorthalidone)
Study: 2109522
Drug: Atenolol alone
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol alone (100 mg daily)
Study: 2109522
Drug: Chlorthalidone alone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone alone (25 mg daily)
Study: 2109522
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) plus Chlorthalidone (25 mg) taken separately
Study: 6975811
Drug: Oral chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloramphenicol (75 mg/kg/day)
Study: 6975811
Drug: Intravenous chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous chloramphenicol
Study: 6975811
Drug: Oral chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloramphenicol
Study: 30990777
Drug: Porcine-based wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine-based wound matrix dressing plus negative pressure wound therapy (NPWT)
Study: 3074608
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg/day)
Study: 28593473
Drug: Erenumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (AMG 334); subcutaneous administration; pharmacokinetics characterized by a two-compartment target-mediated drug disposition model; absorption half-life of 1.6 days; bioavailability of 74%.
Study: 25069999
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (sclerotherapy and Nd:YAG laser)
Study: 30954486
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid (UA) treatment
Study: 15284771
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 mg every 4 hours up to 6 doses)
Study: 15284771
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (administered by standardized protocol)
Study: 11376176
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment within 12 hours of symptom onset
Study: 9382054
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (mesalamine enema and mesalamine tablets)
Study: 9382054
Drug: Mesalamine rectal
Normalized name: mesalamine Rectal Foam
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine rectal enema
Study: 9382054
Drug: Oral mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mesalamine tablets
Study: 8257143
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) fluconazole, 100 mg, administered by constant-rate infusion over 30 min
Study: 8257143
Drug: Oral (p.o.)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (p.o.) fluconazole, 100 mg
Study: 8257143
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) fluconazole, 100 mg
Study: 4085410
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tiapride
Study: 30082217
Drug: Intranasal arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal arginine vasopressin (AVP)
Study: 24176199
Drug: Active Treatment
Normalized name: Active
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Treatment (AT, n=149)
Study: 24176199
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment Control (DTC, n=130)
Study: 20228458
Drug: Oral lycopene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lycopene 8 mg daily with radiotherapy
Study: 15948817
Drug: NP-LS regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP-LS regimen (prepackaged low-residue diet with LoSo Prep containing magnesium citrate, bisocodyl tablets, and bisocodyl suppository)
Study: 15948817
Drug: 2F regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2F regimen (clear liquid diet with double-dose sodium phosphate)
Study: 9177625
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg prolonged-release diclofenac sodium
Study: 9177625
Drug: 3 enteric-coated
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 enteric-coated tablets/day of 50 mg diclofenac sodium
Study: 8191328
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg prostaglandin E2 (PGE2) gel extra‐amniotically
Study: 8191328
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg prostaglandin F2 alpha (PGF2 alpha) intra‐amniotically
Study: 3546147
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg t.i.d. orally for ten days
Study: 3546147
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g t.i.d. orally for ten days
Study: 23065358
Drug: No cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cell therapy (controls)
Study: 21392602
Drug: Autologous mesenchymal
Normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous mesenchymal stem cells (MSCs) administered transendocardially
Study: 21392602
Drug: Whole bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole bone marrow mononuclear cells (BMCs) administered transendocardially
Study: 15156256
Drug: Sulodexide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide treatment for 24 months after 6 months of oral anticoagulants.
Study: 15156256
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sulodexide treatment).
Study: 15156256
Drug: Sulodexide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide treatment for 24 months.
Study: 9256141
Drug: Dolasetron (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (2.4 mg/kg I.V. prechemotherapy, followed by 200 mg oral once daily for 6 days)
Study: 9256141
Drug: Ondansetron (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (32 mg I.V. or 8 mg orally twice daily)
Study: 9256141
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to dolasetron
Study: 9256141
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to ondansetron
Study: 8289411
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition through a subclavian venous catheter (group B)
Study: 2941052
Drug: Diane (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane (high dose cyproterone acetate with ethinyloestradiol)
Study: 2941052
Drug: Minovlar (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minovlar (standard oestrogen and progestagen contraceptive pills)
Study: 2941052
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CPA
Study: 27358493
Drug: TGF-β1 as
Normalized name: Anti-TGF-beta 2G7
DrugBank: 2G7 (DB18589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-β1 as inhibitor of mitochondrial regulators and insulin signaling
Study: 18451243
Drug: weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly docetaxel
Study: 16416385
Drug: Artemisinin-retinol combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-retinol combination
Study: 12574177
Drug: Risedronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 2.5 mg/d
Study: 8912123
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily; n = 20)
Study: 8912123
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily; n = 18)
Study: 26416147
Drug: Early BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early BCG vaccine
Study: 24628498
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg) after 2 weeks of open-label treatment
Study: 24628498
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg) titrated at Weeks 4 or 6
Study: 24628498
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg for 12 weeks)
Study: 21767239
Drug: HAART therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART therapy for 6 months
Study: 21767239
Drug: HAART therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART therapy for 12 months
Study: 19649993
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow cell (BMC) transplantation, intracoronary injection mean 7 days after STEMI
Study: 15181616
Drug: t-TG/antigliadin antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: t-TG/antigliadin antibodies (AGA) stick
Study: 12520747
Drug: Nedaplatin single
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin single drug (100 mg/m2, i.v., every 3 weeks)
Study: 9579495
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg bolus, followed by 125 microg/ml via PCA)
Study: 9579495
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (100 microg bolus, followed by 25 microg/ml via PCA)
Study: 7657965
Drug: Attapulgite (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attapulgite (600 mg tablets)
Study: 2575766
Drug: suriclone (1.50‐2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: suriclone (1.50‐2.25 mg/d)
Study: 2575766
Drug: lorazepam (5.0‐7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (5.0‐7.5 mg/d)
Study: 865585
Drug: Conventional sunburn‐spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sunburn‐spectrum light in gradually increasing doses
Study: 26065565
Drug: Selective COX-2
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective COX-2 inhibitor (celecoxib)
Study: 26065565
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug (indomethacin)
Study: 21872857
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (10 mg/kg)
Study: 11022267
Drug: Rush Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush Immunotherapy (RIT)
Study: 11022267
Drug: Conventional Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Immunotherapy (CIT)
Study: 1350686
Drug: Vecuronium (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.05 mg/kg)
Study: 1350686
Drug: Atracurium (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.25 mg/kg)
Study: 30048574
Drug: No endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endocrine therapy for ER+ DCIS
Study: 25439407
Drug: Propofol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.6 mg/kg + Ketamine 0.8 mg/kg + Midazolam 0.06 mg/kg (three-drug group)
Study: 25439407
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg/kg (single-drug group)
Study: 19176733
Drug: green tea-caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with adequate protein (AP) diet (50-60 g protein/d)
Study: 19176733
Drug: green tea-caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with high-protein (HP) diet (100-120 g protein/d)
Study: 19176733
Drug: adequate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adequate protein (AP) diet (50-60 g protein/d) + placebo
Study: 11207837
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received identical physiotherapeutic treatment 2 times a week, excluding strengthening and balance training
Study: 7999459
Drug: Estrogen-replacement therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-replacement therapy (ERT) with Premarin at 0.625 mg, days 1-25
Study: 29249584
Drug: UFT/LV (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (300-600 mg/d UFT with 75 mg/d LV on days 1-28, every 35 days, for 5 cycles)
Study: 29249584
Drug: SOX (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX (100 mg/m2 of oxaliplatin on day 1 with 80-120 mg/d S-1 on days 1-14, every 21 days, for 8 cycles)
Study: 28797414
Drug: Low transaortic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low transaortic flow rate (FR) defined as <200 ml/s
Study: 23921143
Drug: Erythropoiesis-stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agent (ESA)
Study: 17853395
Drug: Gabapentin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (target dose, 2700 mg) for 6 weeks
Study: 9696975
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative intestinal preparation (n = 53)
Study: 1095964
Drug: S-adenosylmethionine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (150 mg daily) and vitamin B-12 (2000 gamma)
Study: 29730393
Drug: Traditional graded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional graded activity or graded exposure therapies
Study: 26279073
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg chromium picolinate supplements
Study: 24179293
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light (∼3000 lux, ∼7 Watts/m(2)) + melatonin (5 mg)
Study: 24179293
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light (∼1.9 lux, ∼0.6 Watts/m(2)) + melatonin (5 mg)
Study: 18805524
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (20 mg daily)
Study: 9886891
Drug: orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: orlistat 120 mg three times a day (tid)
Study: 7987364
Drug: Midluteal phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midluteal phase (ML) at 35% intensity
Study: 7987364
Drug: Midluteal phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midluteal phase (ML) at 60% intensity
Study: 7987364
Drug: Midluteal phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midluteal phase (ML) at 75% intensity
Study: 2736696
Drug: Li Dan
Normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Li Dan Ling treatment group
Study: 1098726
Drug: Peroperative intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroperative intermittent calf compression with low-dose heparin
Study: 1098726
Drug: Peroperative intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroperative intermittent calf compression without low-dose heparin (control)
Study: 24431394
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks
Study: 19825777
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surgery with functional after-treatment
Study: 19825777
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment by functional bracing
Study: 15388005
Drug: Toremifene plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene plus MVP chemotherapy (mitomycin, vindesin, and cisplatin)
Study: 15388005
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (MVP chemotherapy only)
Study: 15388005
Drug: Pre-treatment arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment arm (previously treated with chemotherapy)
Study: 11399102
Drug: Hyaluronan (Hyalgan),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan (Hyalgan), 20 mg/2 ml once a week for 5 weeks
Study: 11399102
Drug: Methylprednisolone (Depo‐Medrol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (Depo‐Medrol, 40 mg/1 ml once a week for 3 weeks)
Study: 9416723
Drug: Aprotinin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (total dose, 6 x 10(6) kallikrein inactivator units)
Study: 9416723
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (total dose, 270 mg/kg)
Study: 8495761
Drug: Superovulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superovulation with adjunctive leuprolide acetate (LA) therapy
Study: 8495761
Drug: Superovulation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Superovulation without adjunctive leuprolide acetate (LA) therapy
Study: 3122065
Drug: Exercise 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise 3 times weekly for 1 month
Study: 3122065
Drug: Exercise 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise 7 times weekly for 1 month
Study: 3122065
Drug: Exercise 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise 3 times weekly for 1 year
Study: 3122065
Drug: Exercise 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise 3 times weekly after cessation of long-term drug therapy
Study: 29976277
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once daily for 1 week followed by 20 mg once daily (intensive treatment group, IT group, n=49)
Study: 29976277
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg once daily (standard treatment group, ST group, n=54)
Study: 29976277
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once daily for 1 week followed by 20 mg once daily (intensive treatment group, IT group)
Study: 29976277
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg once daily (standard treatment group, ST group)
Study: 26988432
Drug: 14% Plai
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14% Plai cream
Study: 26988432
Drug: 7% Plai
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% Plai cream
Study: 12136225
Drug: Informational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Informational intervention (specific, objective information about radiation treatments)